FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362592327> ?p ?o ?g. }

• W4362592327 endingPage "4092" @default.
• W4362592327 startingPage "4092" @default.
• W4362592327 abstract "Abstract CAR T cell therapy has represented an exciting breakthrough in the treatment of patients with hematologic malignancies. In contrast, the antitumor activity of CAR T cell therapy in solid tumors has been modest so far in clinical studies. The suboptimal clinical efficacy is a result of multiple factors including limited T cell trafficking, persistence, and the immunosuppressive tumor microenvironment (TME). While current strategies utilize costimulatory molecules and cytokines to activate CAR T cells, a key but largely overlooked problem of CAR T cell therapy is nutrient competition between tumor cells and T cells in the nutrient-poor TME. In our previous studies, a metabolic screen identified inosine as an alternative fuel for T cells which can support T cell growth and function in the absence of glucose. T cells could metabolize inosine into hypoxanthine and phosphorylated ribose by purine nucleoside phosphorylase. Moreover, we demonstrated that T cells have advantage over cancer cells in utilizing inosine, and supplementation with inosine enhances the antitumor efficacy of PD-1 mAb and adoptive T cell transfer in mouse models. In this study, we therefore engineered CAR T cells to express CD26 on the cell surface and a secreted adenosine deaminase (ADA) fused with an anchor. These metabolic reprogrammed CAR (designated as MRCAR) T cells exerts their activities through different mechanisms. ADA irreversibly converts adenosine to inosine, overcoming adenosine-mediated immunosuppression and providing inosine for CAR T cell growth, while CD26 induces a rich chemokine receptor profile enabling CAR T cells to traffic to solid tumors. We demonstrated that CD26-overexpressed CAR T cells displayed superior migration capacity and resisted TGF-beta suppression, while the CD26 expression on unmodified CAR T cells was significantly down-regulated by TGF-beta. We further proved that ADA is conditionally secreted in stress condition (i.e., low pH, lack of nutrient and oxygen) based on ADA’s biological characteristics, suggesting that ADA activates CAR T cells as a trans-signaling to the CAR construct in a tumor specific manner. Remarkably, we observed that the MRCAR T cells inhibit tumor growth more effectively than unmodified CAR T cells in both Huh7 human hepatocellular carcinoma (GPC3-MRCAR) and A549 human non-small cell lung cancer (HER2-MRCAR) mouse models. Thus, MR-CAR T cell therapy represents a promising approach to improve CAR T cell therapy against solid tumors. Citation Format: Yue Hu, Abhijit Sarkar, Kevin Song, Magnus Hook, Andras Heczey, Xiaotong Song. Development of nucleotide metabolic reprogrammed CAR T cell therapy suitable for solid tumors. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4092." @default.
• W4362592327 created "2023-04-06" @default.
• W4362592327 creator A5001339474 @default.
• W4362592327 creator A5003946047 @default.
• W4362592327 creator A5021334593 @default.
• W4362592327 creator A5062527254 @default.
• W4362592327 creator A5082219172 @default.
• W4362592327 creator A5086115833 @default.
• W4362592327 date "2023-04-04" @default.
• W4362592327 modified "2023-10-18" @default.
• W4362592327 title "Abstract 4092: Development of nucleotide metabolic reprogrammed CAR T cell therapy suitable for solid tumors" @default.
• W4362592327 doi "https://doi.org/10.1158/1538-7445.am2023-4092" @default.
• W4362592327 hasPublicationYear "2023" @default.
• W4362592327 type Work @default.
• W4362592327 citedByCount "0" @default.
• W4362592327 crossrefType "journal-article" @default.
• W4362592327 hasAuthorship W4362592327A5001339474 @default.
• W4362592327 hasAuthorship W4362592327A5003946047 @default.
• W4362592327 hasAuthorship W4362592327A5021334593 @default.
• W4362592327 hasAuthorship W4362592327A5062527254 @default.
• W4362592327 hasAuthorship W4362592327A5082219172 @default.
• W4362592327 hasAuthorship W4362592327A5086115833 @default.
• W4362592327 hasConcept C181199279 @default.
• W4362592327 hasConcept C185592680 @default.
• W4362592327 hasConcept C203014093 @default.
• W4362592327 hasConcept C2776090121 @default.
• W4362592327 hasConcept C2776107976 @default.
• W4362592327 hasConcept C2776476023 @default.
• W4362592327 hasConcept C2776991684 @default.
• W4362592327 hasConcept C2777610669 @default.
• W4362592327 hasConcept C34628245 @default.
• W4362592327 hasConcept C502942594 @default.
• W4362592327 hasConcept C55493867 @default.
• W4362592327 hasConcept C71615608 @default.
• W4362592327 hasConcept C86803240 @default.
• W4362592327 hasConcept C8891405 @default.
• W4362592327 hasConcept C95444343 @default.
• W4362592327 hasConceptScore W4362592327C181199279 @default.
• W4362592327 hasConceptScore W4362592327C185592680 @default.
• W4362592327 hasConceptScore W4362592327C203014093 @default.
• W4362592327 hasConceptScore W4362592327C2776090121 @default.
• W4362592327 hasConceptScore W4362592327C2776107976 @default.
• W4362592327 hasConceptScore W4362592327C2776476023 @default.
• W4362592327 hasConceptScore W4362592327C2776991684 @default.
• W4362592327 hasConceptScore W4362592327C2777610669 @default.
• W4362592327 hasConceptScore W4362592327C34628245 @default.
• W4362592327 hasConceptScore W4362592327C502942594 @default.
• W4362592327 hasConceptScore W4362592327C55493867 @default.
• W4362592327 hasConceptScore W4362592327C71615608 @default.
• W4362592327 hasConceptScore W4362592327C86803240 @default.
• W4362592327 hasConceptScore W4362592327C8891405 @default.
• W4362592327 hasConceptScore W4362592327C95444343 @default.
• W4362592327 hasIssue "7_Supplement" @default.
• W4362592327 hasLocation W43625923271 @default.
• W4362592327 hasOpenAccess W4362592327 @default.
• W4362592327 hasPrimaryLocation W43625923271 @default.
• W4362592327 hasRelatedWork W1032243866 @default.
• W4362592327 hasRelatedWork W1514853126 @default.
• W4362592327 hasRelatedWork W1526669333 @default.
• W4362592327 hasRelatedWork W1564314651 @default.
• W4362592327 hasRelatedWork W1995313567 @default.
• W4362592327 hasRelatedWork W1996136339 @default.
• W4362592327 hasRelatedWork W2038622193 @default.
• W4362592327 hasRelatedWork W2057706485 @default.
• W4362592327 hasRelatedWork W2411583625 @default.
• W4362592327 hasRelatedWork W87191576 @default.
• W4362592327 hasVolume "83" @default.
• W4362592327 isParatext "false" @default.
• W4362592327 isRetracted "false" @default.
• W4362592327 workType "article" @default.